In the meantime, Sanofi remains “very confident” in the Beyfortus readouts it’s published thus far, he said. Speaking to the data on protection afforded by Beyfortus through six months ...

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of this immunization to ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Sanofi forecasts Beyfortus sales for the fourth quarter to be similar to the third quarter. Price Action: SNY stock is up 2.82% at $53.52 during the premarket session at the last check on Friday.

For 2025, Sanofi reiterated expectations of a “strong rebound” in earnings, driven by pipeline advancements and geographic expansion efforts for key products like Beyfortus. In research ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...